Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy

July 2, 2018 0 By CH Unnikrishnan

Aruna D. Pradhan et al has evaluated residual inflammatory risk among 9,738 patients participating in the Studies of proprotein convertase subtilisin-kexin type 9 (PCSK9) Inhibition and the Reduction of Vascular Events (SPIRE)-1 and -2 cardiovascular outcomes trials who were receiving both statin therapy and bococizumab. At 14 weeks, the mean percent change in LDL-C among statin treated patients who additionally received bococizumab was -60.5% as compared to 6.6% for high sensitivity C-reactive protein (hsCRP). Incidence rates for future cardiovascular events for patients treated with both statin therapy and bococizumab according to on treatment levels of hsCRP <1, 1-3, and >3 mg/L were 1.96, 2.50, and 3.59 events per 100 person-years, respectively. Evidence of residual inflammatory risk persisted among patients treated with both statin therapy and PCSK9 inhibition.